In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Sergey A SheinDepartment of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.ORCID 0000-0003-0258-425X Anna A KorchaginaDepartment of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.ORCID 0000-0001-6177-2379 Zhao LaiDepartment of Molecular Medicine, UTHSCSA, San Antonio, TX, USA.
Ekaterina KorolevaDepartment of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.ORCID 0000-0003-1857-9199 Alexei V TumanovDepartment of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.ORCID 0000-0001-6042-0152 Funding
TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1MLymphotoxin-Beta Receptor Peripheral Signaling Regulates the Transition to Inflammation and Neuropathy-Induced Chronic PainR01NS112263 · NINDS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI AKOPIAN, ARMEN N, TUMANOV, ALEXEI V · 2020 to 2024
$2.4MThe role of lymph node structural organization in naïve T cell decline with ageR01AG080037 · NIA · MAYO CLINIC ARIZONA · PI Jessica N Lancaster · 2023 to 2026
$2.4MAdvancing Cancer Research Through Next Generation Sequencing at Mays Cancer Center of UT Health San AntonioR50CA265339 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Zhao Lai · 2022 to 2026
$957kHigh Throughput DNA Sequencer: Illumina HiSeq 3000 SequencerS10OD021805 · OD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LAI, ZHAO · 2016 to 2016
$600kFACSAria Fusion cell sorter for Flow Cytometry Shared ResourceS10OD030432 · OD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BERTON, MICHAEL T · 2022 to 2022
$596kNCI NIH HHS P30 CA054174NCI NIH HHS R50 CA265339NIA NIH HHS R01 AG080037NIH HHS S10 OD021805NIH HHS S10 OD030432NINDS NIH HHS R01 NS112263
6 · The paper itselfAbstract
The major barrier to clinical translation of αCD137 immunotherapy is separating antitumor efficacy from hepatotoxicity driven by IFN-γ-producing CD8 T cells. We propose a strategy to limit toxicity by promoting contraction of excessively expanded CD8 T cells. We identify CD11c
Indexed as
CD8-Positive T-LymphocytesImmunotherapyAnimalsFemaleInterferon-gammaLymphotoxin beta ReceptorMaleMiceMice, Inbred C57BLSignal TransductionTumor Necrosis Factor Receptor Superfamily, Member 9Interferon-gammaLymphotoxin beta ReceptorTumor Necrosis Factor Receptor Superfamily, Member 9
Identifiers
PMID42018612
PMCPMC13101849
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390